Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing immune-programming science, collaboration milestones, and clinical-trial risks inside Vir Biotechnology鈥檚 SEC paperwork can feel daunting. R&D expense footnotes tied to monoclonal-antibody development or siRNA platform advances sprawl across hundreds of pages. Investors searching for Vir Biotechnology insider trading Form 4 transactions or wondering how a pandemic-response grant affected cash flow often sift through complex language before finding answers.
Stock Titan solves that problem. Our AI engine delivers plain-language highlights the moment a Vir Biotechnology quarterly earnings report 10-Q filing appears on EDGAR. Need Vir Biotechnology Form 4 insider transactions real-time? You鈥檒l see executive stock moves within minutes, complete with context. Interactive summaries transform the dense 10-K into a Vir Biotechnology annual report 10-K simplified view, while side-by-side comparisons make Vir Biotechnology earnings report filing analysis effortless. We also flag every Vir Biotechnology 8-K material events explained entry鈥攊deal when trial data or partnership updates hit the wire.
Because Vir鈥檚 pipeline depends on milestone payments, many investors track board votes on collaboration terms. Our platform links the Vir Biotechnology proxy statement executive compensation section to performance goals, and AI guidance brings clarity to deferred revenue accounting, enabling deeper understanding of Vir鈥檚 cash runway. Whether you鈥檙e understanding Vir Biotechnology SEC documents with AI for strategic research or monitoring Vir Biotechnology executive stock transactions Form 4 for sentiment clues, Stock Titan offers complete, continuously updated coverage of every filing type鈥�10-Q, 10-K, 8-K, S-3, Form 4鈥攅xplained simply and delivered in real time.
Vir Biotechnology (VIR) filed an 8-K to disclose a material R&D milestone. On 24 Jul 2025 the company dosed the first patient in a Phase 1 trial of VIR-5525, an investigational dual-masked T-cell engager that targets EGFR-expressing tumors. Management reported the event under Item 8.01 and attached the related press release as Exhibit 99.1. No financial results, guidance or partnering details were included.
The dosing signals the formal clinical start of VIR-5525 and expands VIR鈥檚 oncology pipeline beyond its infectious-disease franchise. While the filing does not quantify trial size, endpoints or timelines, Phase 1 initiation is typically a prerequisite for value-creating data read-outs and potential future partnerships. Investors should note, however, that first-in-human studies are high-risk and non-revenue-generating at this stage.
ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).
The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.
Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.
Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA 鈥� FURMO-006) is scheduled to begin 2H 2025.
Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.
Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.
Timeline: closing and delivery are expected on or about 3 July 2025.
Vir Biotechnology, Inc. (VIR) 鈥� Form 144 filing overview
The filing discloses a proposed secondary sale of 66,000 common shares of Vir Biotechnology under Rule 144. The shares were originally acquired on 17 Jan 2017 as pre-IPO stock and are held in the name of an undisclosed insider (the form does not specify the individual or relationship to the issuer). Morgan Stanley Smith Barney LLC, Executive Financial Services, is listed as the broker for the transaction.
- Shares to be sold: 66,000
- Aggregate market value: US $332,640
- Planned sale date: 1 Jul 2025
- Total VIR shares outstanding: 138,238,003
- Percent of shares outstanding: ~0.05 % (66,000 ÷ 138,238,003)
- Exchange: NASDAQ
No sales by the filer have occurred within the prior three months, and the securities were not purchased with non-cash consideration according to the disclosure. The seller certifies awareness of no undisclosed material adverse information and acknowledges potential criminal liability for misstatements.
Given the modest size relative to VIR鈥檚 float and the absence of multiple tranches or recent insider selling, this notice is unlikely to have a material impact on the company鈥檚 capital structure or market dynamics. However, investors may monitor for additional filings that could signal a broader disposition program.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
What is the primary focus of Vir Biotechnology?
What technology platforms does the company employ?
How does Vir Biotechnology generate its revenue?
What therapeutic areas are covered by its research pipeline?
How does the company differentiate itself in a competitive market?
What is the significance of its multi-platform approach?
Does the company rely solely on internal development for its products?
How is the company's scientific methodology reflected in its business model?
